Company intelligence / Profile preview

Elektra

South San Francisco, California, United Stateselektra.com ↗

Ownership: Private
Development stage: Commercial

Overview

Electra Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibodies targeting the SIRP family of proteins. Its lead program, ELA026, is in Phase 1 clinical trials for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and life-threatening hyperinflammatory condition with no approved treatments. ELA026 has received FDA Fast Track designation. The company also has additional preclinical programs in immunology and cancer.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Monoclonal antibodyAntibody (general, for pipeline breadth)
Industry: Biotech

Beyond the preview

Go deeper on Elektra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elektra.

Explore the full profile